Detection of MYD88 L265P in Peripheral Blood of Patients with Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 Feb 11

PMID 24509637

Citations 43

Authors

L Xu

Z R Hunter

G Yang

Y Cao

X Liu

R Manning

C Tripsas

J Chen

C J Patterson

M Kluk

S Kanan

J Castillo

N Lindeman

S P Treon

Affiliations

Soon will be listed here.

Abstract

MYD88 L265P is highly prevalent in Waldenstrom's Macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (MGUS). We investigated whether MYD88 L265P could be identified by peripheral blood (PB) allele-specific PCR. MYD88 L265P was detected in untreated WM (114/118; 96.6%); previously treated WM (63/102; 61.8%); and IgM MGUS (5/12; 41.7%) but in none of 3 hyper-IgM or 40 healthy individuals. Median PB MYD88 L265P ΔCt was 3.77, 7.24, 10.89, 12.33 and 14.07 for untreated WM, previously treated WM, IgM MGUS, hyper-IgM and healthy individuals, respectively (P<0.0001). For the 232 IgM MGUS and WM patients, PB MYD88 L265P ΔCt moderately correlated to bone marrow (BM) disease (r=-0.3553; P<0.0001), serum IgM (r=-0.3262; P<0.0001) and hemoglobin (r=0.3005; P<0.0001) levels. PB MYD88 L265P ΔCt and serum IgM correlated similarly with BM disease burden. For positive patients, PB MYD88 L265P ΔCt was <6.5 in 100/114 (88%) untreated WM, and >6.5 in 4/5 (80%) IgM MGUS patients (P=0.0034). Attainment of a negative PB MYD88 L265P mutation status was associated with lower BM disease (P=0.001), serum IgM (P=0.019) and higher hemoglobin (P=0.004) levels in treated patients. These studies show the feasibility for detecting MYD88 L265P by PB examination, and the potential for PB MYD88 L265P ΔCt use in the diagnosis and management of WM patients.

Citing Articles

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems.

Bibas M, Sarosiek S, Castillo J Mediterr J Hematol Infect Dis. 2024; 16(1):e2024061.

PMID: 38984103 PMC: 11232678. DOI: 10.4084/MJHID.2024.061.

Circulating tumor cells in Waldenström macroglobulinemia.

Boccon-Gibod C, Sourdeau E, Morel P, Chapiro E, Nguyen-Khac F, Bravetti C Leukemia. 2024; 38(4):903-907.

PMID: 38332185 DOI: 10.1038/s41375-024-02156-3.

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88 and CXCR4 mutations and underlying haemopathy.

Gueremy A, Boucraut J, Boudjarane J, Grapperon A, Fortanier E, Farnault L J Neurol. 2023; 271(3):1320-1330.

PMID: 37979093 DOI: 10.1007/s00415-023-12068-4.

Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis.

Montesdeoca S, Garcia-Gisbert N, Calvo X, Arenillas L, Roman D, Fernandez-Rodriguez C Cancers (Basel). 2023; 15(16).

PMID: 37627180 PMC: 10452547. DOI: 10.3390/cancers15164152.

MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.

Drandi D, Ferrante M, Borriero M, Ferrero S Methods Mol Biol. 2023; 2621:57-72.

PMID: 37041440 DOI: 10.1007/978-1-0716-2950-5_5.

References

Treon S, Hunter Z, Matous J, Joyce R, Mannion B, Advani R . Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007; 13(11):3320-5. DOI: 10.1158/1078-0432.CCR-06-2511. View

Landgren O, Staudt L . MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012; 367(23):2255-6. DOI: 10.1056/NEJMc1211959. View

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

Treon S, Xu L, Yang G, Zhou Y, Liu X, Cao Y . MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367(9):826-33. DOI: 10.1056/NEJMoa1200710. View

Puente X, Pinyol M, Quesada V, Conde L, Ordonez G, Villamor N . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-5. PMC: 3322590. DOI: 10.1038/nature10113. View

Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R . Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood. 2013; 121(13):2522-8. DOI: 10.1182/blood-2012-09-457101. View

Hodge L, Ziesmer S, Yang Z, Secreto F, Gertz M, Novak A . IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. Blood. 2012; 120(18):3774-82. DOI: 10.1182/blood-2012-03-419440. View

Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D . IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia. 2012; 27(1):183-9. DOI: 10.1038/leu.2012.257. View

Smith B, Robert N, Ault K . In Waldenstrom's macroglobulinemia the quantity of detectable circulating monoclonal B lymphocytes correlates with clinical course. Blood. 1983; 61(5):911-4. View

10.

Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A . Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2011; 119(1):192-5. DOI: 10.1182/blood-2011-08-371179. View

11.

Kiss T, Xu W, Jamal N, Messner H . Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia. Leuk Lymphoma. 1999; 34(5-6):493-500. DOI: 10.3109/10428199909058476. View

12.

Passamonti F . How I treat polycythemia vera. Blood. 2012; 120(2):275-84. DOI: 10.1182/blood-2012-02-366054. View

13.

Jimenez C, Sebastian E, Chillon M, Giraldo P, Mariano Hernandez J, Escalante F . MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia. 2013; 27(8):1722-8. DOI: 10.1038/leu.2013.62. View

14.

Loiarro M, Gallo G, Fanto N, De Santis R, Carminati P, Ruggiero V . Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem. 2009; 284(41):28093-28103. PMC: 2788860. DOI: 10.1074/jbc.M109.004465. View

15.

Anderson K, Alsina M, Bensinger W, Biermann J, Cohen A, Devine S . Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013; 11(1):11-7. DOI: 10.6004/jnccn.2013.0004. View

16.

Xu L, Hunter Z, Yang G, Zhou Y, Cao Y, Liu X . MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013; 121(11):2051-8. PMC: 3596964. DOI: 10.1182/blood-2012-09-454355. View

17.

Treon S . How I treat Waldenström macroglobulinemia. Blood. 2009; 114(12):2375-85. DOI: 10.1182/blood-2009-05-174359. View

18.

Owen R, Treon S, Al-Katib A, Fonseca R, Greipp P, McMaster M . Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30(2):110-5. DOI: 10.1053/sonc.2003.50082. View

19.

Ondrejka S, Lin J, Warden D, Durkin L, Cook J, Hsi E . MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013; 140(3):387-94. DOI: 10.1309/AJCP10ZCLFZGYZIP. View

20.

Argentou N, Vassilopoulos G, Ioannou M, Germenis A, Speletas M . Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders. Leukemia. 2013; 28(2):447-9. DOI: 10.1038/leu.2013.294. View